Kymera Therapeutics Inc
NASDAQ:KYMR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.9
52.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Kymera Therapeutics Inc
Wall Street
Price Targets
KYMR Price Targets Summary
Kymera Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
KYMR
is 60.18 USD
with a low forecast of 41.41 USD and a high forecast of 94.5 USD.
KYMR Last Price Targets
Kymera Therapeutics Inc
The latest public price target was made on Sep 27, 2024 by
Jeff Jones
from
Oppenheimer
,
who expects
KYMR
stock to
rise by 38%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Jeff Jones
Oppenheimer
|
56
USD
Upside 38% |
2 months ago
Sep 27, 2024
|
Kymera Therapeutics price target raised to $56 from $52 at Oppenheimer
TheFly
|
Andy Chen
Wolfe Research
|
65
USD
Upside 60% |
3 months ago
Aug 26, 2024
|
Kymera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
TheFly
|
|
Andrew Fein
H.C. Wainwright
|
60
USD
Upside 48% |
4 months ago
Aug 8, 2024
|
Kymera Therapeutics (KYMR) PT Raised to $60 at H.C. Wainwright
StreetInsider
|
|
Andrew Fein
H.C. Wainwright
|
46
USD
Upside 13% |
6 months ago
Jun 17, 2024
|
H.C. Wainwright Reiterates Buy Rating on Kymera Therapeutics (KYMR)
StreetInsider
|
Edward Tenthoff
Piper Sandler
|
56
USD
Upside 38% |
6 months ago
May 23, 2024
|
Piper Sandler Reiterates Overweight Rating on Kymera Therapeutics (KYMR)
StreetInsider
|
|
Jeff Jones
Oppenheimer
|
52
USD
Upside 28% |
7 months ago
May 3, 2024
|
Kymera Therapeutics (KYMR) PT Lowered to $52 at Oppenheimer
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is KYMR's stock price target?
Price Target
60.18
USD
According to Wall Street analysts, the average 1-year price target for
KYMR
is 60.18 USD
with a low forecast of 41.41 USD and a high forecast of 94.5 USD.
What is Kymera Therapeutics Inc's Revenue forecast?
Projected CAGR
3%
For the last 4 years the
compound annual growth rate for
Kymera Therapeutics Inc's revenue is
128%.
The projected
CAGR
for the next 4 years is
3%.
You don't have any saved screeners yet
